10x Genomics News

10x Genomics First Quarter 2024 Earnings: In Line With Expectations

Yahoo Finance18:34

Insider Moves Spark Speculation: 10X Genomics Executives Rethink Stock Sale Strategies

TipRanks14:03

UBS Adjusts 10x Genomics Price Target to $30 From $52, Maintains Neutral Rating

10x Genomics (TXG) has an average rating of outperform and price targets ranging from $26 to $62, according to analysts polled by Capital IQ. Price: 26.91, Change: -2.37, Percent Change: -8.09

MT Newswires00:59

10x Genomics Cut to Hold From Buy by TD Cowen

10x Genomics Cut to Hold From Buy by TD Cowen

Dow Jones00:37

TD Cowen: Downgraded 10x Genomics (TXG.US) rating from buy to hold, and adjusted target price from $57.00 to $32.00.

TD Cowen: Downgraded 10x Genomics (TXG.US) rating from buy to hold, and adjusted target price from $57.00 to $32.00.

Zhitong Finance00:30

10x Genomics, Inc. (NASDAQ:TXG) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 1 23:33

10x Genomics Is Maintained at Buy by Stifel

10x Genomics Is Maintained at Buy by Stifel

Dow JonesMay 1 21:12

10x Genomics Price Target Cut to $53.00/Share From $63.00 by Stifel

10x Genomics Price Target Cut to $53.00/Share From $63.00 by Stifel

Dow JonesMay 1 21:12

Stifel Maintains Buy on 10x Genomics, Lowers Price Target to $53

Stifel analyst Daniel Arias maintains 10x Genomics with a Buy and lowers the price target from $63 to $53.

Analyst UpgradesMay 1 21:01

10x Genomics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 105.43% Stifel $63 → $53 Maintains Buy 04/29/2024 93.8% Canaccord Genuity $65 → $50 Maintains B

BenzingaMay 1 21:00

Earnings Call Summary | 10x Genomics(TXG.US) Q1 2024 Earnings Conference

The following is a summary of the 10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript:Financial Performance:10x Genomics reported Q1 total revenue growth of 5% to $141 million.Consumption revenu

Futu NewsMay 1 19:26 · Conference Call

Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)

TipRanksMay 1 18:50

Analysts' Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)

TipRanksMay 1 15:41

The European Unified Patent Court Clears Curio Seeker With Respect To Claim 1 Of EP 2697391 Asserted By 10x Genomics

The European Unified Patent Court (UPC) today announced a finding that Curio Seeker does not infringe main claim 1 of EP 2697391 asserted by 10x Genomics (NASDAQ:TXG). The UPC has also ordered Curio B

BenzingaMay 1 15:27

10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...

Yahoo FinanceMay 1 15:27

Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)

Court finds non-infringement by Curio Seeker with respect to over-reaching claim by 10x Genomics Curio Bioscience, a leading innovator of high-precision tools for the life sciences industry, today announced that a

BusinesswireMay 1 13:01

10x Genomics Shares Are Trading Lower Following Worse-than-expected Q1 Results.

10x Genomics Shares Are Trading Lower Following Worse-than-expected Q1 Results.

BenzingaMay 1 05:58

10x Genomics Inc (TXG) Q1 2024 Earnings: Misses Analyst Expectations Amidst New Product Launches

Yahoo FinanceMay 1 05:43

Research Alert: CFRA Maintains Buy Opinion On Shares Of 10x Genomics, Inc.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We decrease our target price to $41 from

MT NewswiresMay 1 05:35

10x Genomics Maintains 2024 Revenue Guidance Of $670M-$690M (Est $677.79M), Representing 8%-12% Growth Y/Y

10x Genomics Maintains 2024 Revenue Guidance Of $670M-$690M (Est $677.79M), Representing 8%-12% Growth Y/Y

BenzingaMay 1 05:06